Disposable Manufacturing Tech

BIOPRODUCTION CONGRESS DUBLIN 2017

Integrating disposable tech? Size matters, says BMS

27-Oct-2017 By Flora Southey

Size can be a restricting factor when introducing single-use technologies into a pre-existing facility according to BMS, which hopes to integrate disposable equipment at a US-based site.

Sartorius Stedim Biotech cuts guidance citing hurricane, destocking and supply problems

25-Oct-2017 By Gareth Macdonald

Sartorius Stedim Biotech (SSB) has cut its full year guidance, citing the negative impact of hurricane Maria, customer destocking and ongoing issues with a cell culture media supplier.

Pall: Quarterly set-backs but hurricanes fail to blow single-use off course

24-Oct-2017 By Dan Stanton

Pall Corporation suffered a significant impact in the third quarter after hurricanes shut down facilities in Puerto Rico and Florida.

Univercells: 'Micro-facilities' to slash the cost of vaccine manufacture

20-Oct-2017 By Cutting the cost of vaccine manufacture, Univercells

High-density single-use bioreactors, small facilities and continuous manufacturing will cut the cost of manufacturing polio vaccines down to $0.15 per dose, says Univercells.

Amgen: Industry must look to next-generation continuous cell harvesting tech

17-Oct-2017 By Dan Stanton

Amgen says it is evaluating Pall’s Cadence Acoustic Separation as a primary cell clarification method for monoclonal antibodies.

News in Brief

MilliporeSigma opens $115m life science centre in Massachusetts

11-Oct-2017 By Staff Reporter

MilliporeSigma has cut the ribbon on a life science site in Burlington that incorporates a biomanufacturing equipment education centre.

Biotech Week Boston

Beyond flexible: Deployable plants offer pay-as-you-go biomanufacturing, says Just

10-Oct-2017 By Dan Stanton

Faster and more flexible biomanufacturing models are necessary to reduce the cost of biologics, says Just Biotherapeutics which is building a deployable modular facility in China.

AbbVie opens biologics plant in Singapore, completing $320m project

06-Oct-2017 By Dan Stanton

AbbVie has opened a mammalian cell culture-based drug manufacturing facility equipped with both stainless and single-use equipment, as part of a $320m investment in Singapore.

Avid selects MilliporeSigma to meet single-use trend

06-Oct-2017 By Flora Southey

Avid Bioservices has installed two MilliporeSigma Mobius 2,000L single-use bioreactors at its facility in Tustin, California, US.

IPS & G-CON launch prefabricated cleanrooms biz

06-Oct-2017 By Flora Southey

Integrated Project Services (IPS) and G-CON Manufacturing are collaborating to supply prefabricated cleanrooms for biomanufacturing, known as PODs.

Exclusive interview from Biotech Week Boston

Balancing the up and downstream: Repligen CEO talks R&D and M&A

03-Oct-2017 By Dan Stanton

Repligen’s customer GE Healthcare opted to make its latest Protein A ligand in-house, but CEO Tony Hunt remains confident in his firm’s long-term partnerships and diversified bioprocessing offering.

Biotech Week Boston

On the roadmap again: Industry to address 'never ending' bioprocessing evolution

27-Sep-2017 By Dan Stanton

The Biophorum Operations Group (BPOG) has begun working on 11 technology development projects after publishing its first roadmap, but the bioprocessing industry’s visions are forever evolving, says Sanofi-Genzyme.

Biotech Week Boston

Brammer leans on Pall for $50m cell & gene therapy plant expansions

27-Sep-2017 By Dan Stanton

The contract development and manufacturing organisation (CDMO) has selected Pall Life Sciences as its single-use equipment partner at its sites in Florida and Massachusetts.

MilliporeSigma opens Chinese bioprocessing centre to showcase tech

27-Sep-2017 By Staff Reporter

MilliporeSigma has opened a biopharma process development and technology centre in China.

Biotech Week Boston

Protein A's mAb capture efficacy offsets cost, says GE launching new offering

26-Sep-2017 By Dan Stanton

GE Healthcare has launched a Protein A resin it says can improve monoclonal antibody purification capacity by up to 40% compared to its current offering.

Momenta: WuXi single-use capacity expansion to support changing biosimilar demand

14-Sep-2017 By Dan Stanton

Momenta says flexibility built into its contract with WuXi Biologics will offset fluctuations in demand for global biosimilars.

Expression yourself: Win an iPad in our bioprocessing survey

12-Sep-2017 By Dan Stanton

Is plastic fantastic? Is stainless still à la mode*? Do Chinese hamsters continue to tow the cell line? Biopharma-Reporter wants your opinions for its second annual biomanufacturing survey.

Gilead aims to expand CAR-T manufacturing capabilities post-Kite acquisition

01-Sep-2017 By Dan Stanton

Gilead says it is committed to driving down costs of CAR-T manufacturing after agreeing to buy late-stage cell and gene therapy firm KitePharma for $11.9bn.

Oxford BioMedica could pocket $100m on Novartis CAR-T cell success

31-Aug-2017 By Dan Stanton

Oxford BioMedica saw its share price jump 21% after the US FDA approved Kymriah, the gene modified cell therapy made with the firm’s lentiviral vectors.

From vendor to tender: Thermo Fisher completes $7.2bn Patheon acquisition

30-Aug-2017 By Dan Stanton

Thermo Fisher has entered the contract development and manufacturing (CDMO) space through the acquisition of Patheon.

MilliporeSigma to buy Natrix Separations with an eye on single use

29-Aug-2017 By Gareth Macdonald

MilliporeSigma has agreed to buy chromatography membrane supplier Natrix Separations to expand its vaccine and mAb production tech offering.

Vendors optimistic for future despite slowdown in growth

18-Aug-2017 By Dan Stanton

Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.

US FDA clarifies what constitutes 'minor' change to biologic production process

09-Aug-2017 By Gareth Macdonald

The US FDA has sought to clarify when biologics firms should inform it about minor changes to manufacturing processes in draft guidance this week.

Repligen closes Spectrum acquisition in latest boost for filtration business

04-Aug-2017 By Dan Stanton

Filtration drove a record quarter for Repligen which says the addition of Spectrum Pharmaceuticals will further grow its bioprocessing portfolio and geographical presence.

Modular single-use facilities rebalance Biopharma’s capacity scales

02-Aug-2017 By Dan Stanton

Modular facilities and single-use systems are fast becoming a standard part of the bioproduction infrastructure as industry looks to mitigate future capacity constraints.

Thermo Fisher: Modest Q2 for life sciences due to ‘lumpiness’ of bioproduction

01-Aug-2017 By Dan Stanton

Muted bioproduction technology pegged back an otherwise strong quarter, but Thermo Fisher says it expects growth will pick up again over time.

Pall: ‘More than ever, process control is a core focus area’

28-Jul-2017 By Dan Stanton

Pall Corporation has developed a control system for its single-use benchtop bioreactor and says it will continue to invest in-house for process control technologies.

Lonza envisions five new plants at Visp for modular manufacturing biz

28-Jul-2017 By Gareth Macdonald

Lonza has started work on a facility to house its new modular tech-based biomanufacturing service at its site in Visp, Switzerland.

Novartis preps production platform for alternative to Lucentis

26-Jul-2017 By Dan Stanton

Novartis has scaled up manufacturing of wet age-related macular degeneration (AMD) monoclonal antibody RTH258 ahead of a potential regulatory submission next year.

Sartorius takes €10m hit on media sales due to Lonza's regulatory woes

26-Jul-2017 By Dan Stanton

Supply chain issues stemming from an FDA warning letter at a facility run by its partner Lonza have dampened Sartorius Stedim Biotech’s first half 2017 results.

Lonza sets CHF7.5bn 2022 sales target citing pharma drivers

26-Jul-2017 By Gareth Macdonald

Lonza Group AG has predicted it will generate annual revenue of CHF7.5bn ($7.9bn) by 2022, citing recent acquisition Capsugel and its new Visp-based Ibex manufacturing service as drivers.

ABEC breaks the 2,000L ‘plastic ceiling’ with 4,900L single-use bioreactor

12-Jul-2017 By Dan Stanton

ABEC says its latest offering has twice the working volume of the 2,000L bioreactor systems generally deemed to be the upper limit in single-use bioprocessing.

Patheon to spend $45m on manufacturing plants ahead of Thermo takeover

30-Jun-2017 By Gareth Macdonald

Patheon NV has announced it will spend $45m to expand and enhance its manufacturing network citing customer demand for more reliable, flexible and cost-efficient supply chains.

Dispatches from BioPharma Expo, Japan

Lonza expands in Asia: 8,000L single-use in Singapore, regenerative meds in Japan

30-Jun-2017 By Dan Stanton

Lonza will install four 2,000L single-use bioreactors at its Singapore facility to cater for growing demand for small to mid-volume biologics production.

Wuxi Biologics IPO in Hong Kong brings in $511m

16-Jun-2017 By Staff Reporter

Wuxi Biologics (Cayman) Inc. completed a successful IPO on the Hong Kong stock exchange on Tuesday, raising $511m.

US FDA lifts hold on Inovio's cancer vaccine trials after firm answers device questions

15-Jun-2017 By Gareth Macdonald

Inovio Pharmaceuticals has started Phase III trials of its DNA-based human papillomavirus therapy VGX-3100 after the US FDA lifted a clinical hold imposed list year.

Thermo Fisher opens single-use tech testing centre in UK

14-Jun-2017 By Gareth Macdonald

Thermo Fisher has opened a UK test centre to allow biopharmaceutical industry customers to test single-use production technologies.

Securing single-use systems: SSB opts for blockbuster resins and supplier partnerships

06-Jun-2017 By Dan Stanton

Single-use vendors must address their own supply chains to help overcome end-user challenges, says Sartorius.

Amgen: Bioprocess intensification and integration key for next-generation manufacturing

23-May-2017 By Dan Stanton

Its new Singapore single-use plant is a fraction of the size of a conventional commercial facility but next-generation biomanufacturing at Amgen points to even smaller, more integrated sites.

GE looks to single-use modular BioParks to relieve capacity investment risk

23-May-2017 By Dan Stanton

Incorporating single-use and modular facilities into a vendor run bio-campus could reduce CAPEX spend dilemmas faced by drugmakers says GE Healthcare.

Dr Reddy’s turns to single-use for biosimilar production in India

19-May-2017 By Dan Stanton

Dr Reddy’s will expand its biosimilar manufacturing capacity in Hyderabad by 4,000L using GE Healthcare’s FlexFactory platform based on single-use technologies.

Thermo Fisher: $7.2bn Patheon sits in sweet spot for bioproduction business

17-May-2017 By Dan Stanton

Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.

Single-use making its mark in India as Stelis teams with MilliporeSigma

16-May-2017 By Dan Stanton

Stelis Biopharma has partnered with Germany’s Merck on a bioprocessing services centre in Bangalore and says single-use systems could kickstart India’s biomanufacturing sector.

Industry 4.0 making its mark in biomanufacturing sector, Thermo Fisher

10-May-2017 By Dan Stanton

Integrating single-use, automation and continuous processing equipment will be the future for bioproduction says Thermo Fisher acquisition Finesse Solution.

WuXi using Thermo Fisher to equip 28,000L single-use site in China

09-May-2017 By Dan Stanton

A WuXi Biologics facility tipped to be the world’s largest single-use mammalian cell culture site will be equipped with disposable systems from Thermo Fisher.

Correction

Glenmark eyes up 1,000L production line expansion at Swiss plant

09-May-2017 By Dan Stanton

A second single-use production line could offer commercial-scale capacity for bispecific antibodies but Glenmark says it would need to scale-up further to support more traditional biologics.

Latest Avid investment to turn bioreactor capacity up to 11 (thousand litres)

03-May-2017 By Dan Stanton

Avid Bioservices will add multiple MilliporeSigma 2,000L bioreactors at its Californian single-use production plant in an effort to its increase annual revenue to over $100m.

BPI EUROPE 2017

Continuous chromatography and single-use filtration at BPI Europe

03-May-2017 By Dan Stanton

Pall Corporation, GE Healthcare and LEWA Process Technologies showed off their latest downstream offerings to Biopharma-Reporter in Amsterdam last week.

Thermo Fisher collaborates to establish single-use and automation site in China

27-Apr-2017 By Dan Stanton

Mab-Venture Biopharma has entered a collaboration to establish an antibody development and production plant in China incorporating Thermo Fisher’s single-use bioreactors and SmartFactory automated technology.

Filtration is a ‘high value process at a marginal cost,’ says Danaher

25-Apr-2017 By Dan Stanton

Danaher reported mid-single-digit growth from its bioprocessing subsidiary Pall Life Science and expects a continued trajectory to support Biopharma’s filtration needs.